Ana
Fernández Montes
![Foto de Ana](/img/nophoto.png)
![Foto de Hospital Morales Meseguer](/img/noimage_org.png)
Hospital Morales Meseguer
Murcia, EspañaPublicacións en colaboración con investigadores/as de Hospital Morales Meseguer (16)
2024
-
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
British Journal of Cancer, Vol. 130, Núm. 5, pp. 777-787
-
Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry
Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145
-
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686
-
Prospective study of predictors for anxiety, depression, and somatization in a sample of 1807 cancer patients
Scientific reports, Vol. 14, Núm. 1, pp. 3188
-
State of the scientific evidence and recommendations for the management of older patients with gastric cancer
Journal of Geriatric Oncology, Vol. 15, Núm. 3
2023
-
Can Oncologists Prompt Patient Prognostic Awareness to Enhance Decision-Making? Data From the NEOetic Study
Oncologist, Vol. 28, Núm. 11, pp. 986-995
-
Prediction of serious complications in patients with pulmonary thromboembolism and solid cancer: Validation of the EPIPHANY Index in a prospective cohort of patients from the PERSEO study
PLoS ONE, Vol. 18, Núm. 5 May
-
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Therapeutic Advances in Medical Oncology, Vol. 15
-
Toxicities and Quality of Life during Cancer Treatment in Advanced Solid Tumors
Current Oncology, Vol. 30, Núm. 10, pp. 9205-9216
2022
-
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100
-
Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
ESMO Open, Vol. 7, Núm. 3
2021
2020
-
Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry
Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 734-750
2019
-
Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis
Oncologist, Vol. 24, Núm. 8, pp. e687-e695
2018
-
Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis
Journal of Geriatric Oncology, Vol. 9, Núm. 3, pp. 254-264
2016
-
On the effect of triplet or doublet chemotherapy in advanced gastric cancer: Results from a national cancer registry
JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 11, pp. 1379-1388